Dopamine News and Research

Latest Dopamine News and Research

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

Perturbing DISC1 gene could help researchers treat mental illness, says study

Scientists have long eyed mutations in a gene known as DISC1 as a possible contributor to schizophrenia and mood disorders, including depression and bipolar disorder. Now, new research led by Johns Hopkins researchers suggests that perturbing this gene during prenatal periods, postnatal periods or both may have different effects in mice, leading to separate types of brain alterations and behaviors with resemblance to schizophrenia or mood disorders.

6 Jan 2010

Citicoline supplements may reduce cravings and increase satiety

The obesity crisis in the United States has now grown to epidemic proportion. And as the list of consequential health conditions and diseases continues to expand as well, there are major movements toward helping Americans lose weight.

5 Jan 2010

DSPA submits lurasidone NDA to the FDA

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

4 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

Projects investigating placebo effects in Parkinson's disease receive funds

The Michael J. Fox Foundation for Parkinson's Research announced funding for two projects investigating the placebo effect in Parkinson's disease.

30 Dec 2009

Grant of $2 million awarded to understand PIGD in Parkinson's disease

The Michael J. Fox Foundation for Parkinson's Research has awarded a total of $2 million to five research teams carrying out clinical studies to refine understanding of postural instability and gait disturbances (PIGD) in Parkinson's disease, and help speed the development of urgently needed treatments.

29 Dec 2009

Grant of $1 million awarded to develop new treatments for dyskinesia

The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.

22 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Study provides new insight on teens’ addiction to drug abuse

It is common knowledge that smoking is a health risk but why do teens become addicted to smoking more easily than adults? In an evaluation for Faculty of 1000 Biology, Neil Grunberg looks into why adolescents are more prone to substance abuse.

14 Dec 2009

Scientists explore new potential therapies for Parkinson's disease

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.

11 Dec 2009

Asymmetrical arm swings while walking can be an early sign of Parkinson's disease

Irregular arm swings while walking could be an early sign of Parkinson's disease, according to neurologists who believe early detection may help physicians apply treatments to slow further brain cell damage until strategies to slow disease progression are available.

11 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.

9 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Fruit flies are valid models for studying drug addiction in humans, says scientists

Fruit flies may seem like unlikely heroes in the battle against drug abuse, but new research suggests that these insects - already used to study dozens of human disease - could claim that role. Scientists are reporting that fruit flies can be used as a simpler and more convenient animal model for studying the effects of cocaine and other drugs of abuse on the brain.

3 Dec 2009

Dopamine News and Research

Latest Dopamine News and Research

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

MedGenesis Therapeutix enters into license agreement with Amgen

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

Perturbing DISC1 gene could help researchers treat mental illness, says study

Citicoline supplements may reduce cravings and increase satiety

DSPA submits lurasidone NDA to the FDA

Erectile dysfunction linked to RLS in older men

Projects investigating placebo effects in Parkinson's disease receive funds

Grant of $2 million awarded to understand PIGD in Parkinson's disease

Grant of $1 million awarded to develop new treatments for dyskinesia

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Study provides new insight on teens’ addiction to drug abuse

Scientists explore new potential therapies for Parkinson's disease

Asymmetrical arm swings while walking can be an early sign of Parkinson's disease

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Fruit flies are valid models for studying drug addiction in humans, says scientists

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in